Incidence, Prediction, and Prevention of Fractures After Kidney Transplantation: A Systematic Review Protocol.

Background: Kidney transplant recipients are uniquely exposed to the disordered bone metabolism associated with chronic kidney disease beginning before transplantation followed by chronic corticosteroid use after transplantation. Previous efforts to synthesize the rapidly accruing evidence regarding estimation and management of fracture risk in kidney transplant recipients are outdated and incomplete.

Objective: To synthesize the evidence informing the overall incidence, patient-specific risk prediction, and methods of prevention of fractures in patient living with a kidney transplant.

Hybrid attention-based deep neural networks for short-term wind power forecasting using meteorological data in desert regions.

This study introduces an optimized hybrid deep learning approach that leverages meteorological data to improve short-term wind energy forecasting in desert regions. Over a year, various machine learning and deep learning models have been tested across different wind speed categories, with multiple performance metrics used for evaluation. Hyperparameter optimization for the LSTM and Conv-Dual Attention Long Short-Term Memory (Conv-DA-LSTM) architectures was performed.

Solid oxide fuel cell (SOFC) control strategy enhancement by adaptive neuro-fuzzy inference system (ANFIS).

Global warming is a vital problem that many researchers tried to solve with so many solutions such as: reducing electricity production with conventional generators by using renewable energy resources and using hydrogen as an alternative to fossil fuels. The universal Economic crisis came across to cut off certain quantities at scheduled times. This, directly, affects renewable energy sources connected to the grid due to voltage and frequency variations.

Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial.

Objective: We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc).

Methods: This phase II proof-of-concept, single center, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with <5 years since the first non-Raynaud's symptom and/or skin worsening despite immunosuppression who were treated with intravenous brentuximab vedotin 0.6 mg/Kg q3 weeks for 45 weeks.